Article
The co-stimulation of anti-CD28 and IL-2 enhances the sensitivity of ELISPOT assays for detection of neoantigen-specific T cells in PBMC.
Journal of immunological methods - 1 Jan 2000
Tang Yunxia, Zhu Linnan, Xu Qumiao, Zhang Xiuqing, Li Bo, Lee Leo J
Abstract excerpt
Neoantigen-based cancer immunotherapies hold the promise of being a truly personalized, effective treatment for diverse cancer types. ELISPOT assays, as a powerful experimental technique, can verify the existence of antigen specific T cells to support basic clinical research and monitor clinical trials. However, despite the high sensitivity of ELISPOT assays, detecting immune responses of neoantigen specific T...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
